New assets in both businesses -Pharma and CDMO- fuel double-digit growth in net revenues and EBITDA and prove strong strategy execution.
Targeted acquisition and rapid integration expand ESTEVE pharma business portfolio with eight new products in the last 18 months.
CDMO business grows with new assets in the USA, adding early development capabilities.
The company has achieved B Corp Certification reflecting strong commitment to social and environmental standards.

ESTEVE CDMO, the global pure-play CDMO specializing in high-quality small-molecule APIs and advanced pharmaceutical intermediates, today announced that it would add to its plans for the buildout of a new production unit at its facility in Celrà, and launch its new brand identity at DCAT Week in New York.

ESTEVE CDMO, the global pure-play CDMO specializing in high-quality small-molecule APIs and pharmaceutical intermediates, today announced that it had commenced a $15.5-million investment to enhance production capabilities and associated space at its newly acquired North American facility in Morton Grove, Illinois.

The company joins a global movement of more than 10,000 corporations that drives businesses to generate positive impact beyond financial goals.